Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Accent Therapeutics
National Institutes of Health Clinical Center (CC)
Pheon Therapeutics
Orano Med LLC
Novartis
Elicio Therapeutics
GONGCHU Biotechnology Co., Ltd
Novita Pharmaceuticals, Inc.
Compugen Ltd
Compugen Ltd
Revolution Medicines, Inc.
ADC Therapeutics S.A.
Ohio State University Comprehensive Cancer Center
MacroGenics
MacroGenics
Novartis
Abramson Cancer Center at Penn Medicine
Masonic Cancer Center, University of Minnesota
AbbVie
National Institutes of Health Clinical Center (CC)
AbbVie
Altor BioScience
Alliance for Clinical Trials in Oncology
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
CritiTech, Inc.
Calando Pharmaceuticals
National Cancer Institute (NCI)
Altor BioScience
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Eisai Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Cancer Research UK
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NYU Langone Health
AstraZeneca
Pharmacyclics LLC.